Payment overview · 2025
General Payments
$2,441.32
99 reported records · 23 companies
Healthcare provider profile · identity verified
Ranilo L Vasquez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROKEN ARROW, OK · NPI 1669449211
Verified facts
What the public records show
CMS Open Payments records show Ranilo L Vasquez, M.D. received $2,441.32 in general payments during 2025 across 99 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $644.26 | 26.4% | 15 | 2025 |
| KVK-Tech, Inc. | Unresolved — no canonical attribution shown | $365.40 | 15.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $155.37 | 6.4% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.95 | 6.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.94 | 6.2% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.99 | 5.7% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $130.81 | 5.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.93 | 4.1% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.09 | 3.9% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $64.80 | 2.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.74 | 2.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.07 | 2.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $54.81 | 2.2% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $44.13 | 1.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.53 | 1.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $39.49 | 1.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.17 | 1.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.59 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.82 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.55 | 0.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.11 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.00 | 0.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.77 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,441.32 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $317.79 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $249.54 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $155.37 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $132.40 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $132.40 | 13 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $130.81 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $130.81 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.07 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $92.90 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $83.14 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $83.14 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.74 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $64.80 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.15 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $59.15 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $59.15 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.07 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $58.88 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $54.81 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.03 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.03 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.09 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $44.13 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $39.49 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $4.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 169 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 89 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 493 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 126 |
| Lisinopril | Lisinopril | 407 | 133 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 331 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 96 |
| Gabapentin | Gabapentin | 262 | 80 |
| Omeprazole | Omeprazole | 248 | 75 |
| Losartan Potassium | Losartan Potassium | 244 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 74 |
| Furosemide | Furosemide | 210 | 76 |
| Metformin Hcl | Metformin Hcl | 207 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 54 |
| Eliquis | Apixaban | 169 | 44 |
| Alprazolam | Alprazolam | 163 | 27 |
| Carvedilol | Carvedilol | 163 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 52 |
| Alendronate Sodium | Alendronate Sodium | 142 | 38 |
| Trazodone Hcl | Trazodone Hcl | 142 | 44 |
| Simvastatin | Simvastatin | 141 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 55 |
| Azithromycin | Azithromycin | 139 | 109 |
| Potassium Chloride | Potassium Chloride | 137 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 30 |
| Memantine Hcl | Memantine Hcl | 129 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 33 |
| Montelukast Sodium | Montelukast Sodium | 119 | 37 |
| Donepezil Hcl | Donepezil Hcl | 111 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 34 |
| Glimepiride | Glimepiride | 105 | 31 |
| Allopurinol | Allopurinol | 103 | 35 |
| Lorazepam | Lorazepam | 103 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 32 |
| Tramadol Hcl | Tramadol Hcl | 98 | 23 |
| Clonazepam | Clonazepam | 89 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 28 |
| Atenolol | Atenolol | 82 | 25 |
| Spironolactone | Spironolactone | 82 | 21 |
| Ozempic | Semaglutide | 78 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | 11 |
| Sertraline Hcl | Sertraline Hcl | 71 | 23 |
| Buspirone Hcl | Buspirone Hcl | 63 | 18 |
| Finasteride | Finasteride | 63 | 23 |
| Meloxicam | Meloxicam | 63 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 53 |
| Glipizide | Glipizide | 61 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 16 |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 54 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Methylprednisolone | Methylprednisolone | 51 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 14 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Famotidine | Famotidine | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 43 | 20 |
| Celecoxib | Celecoxib | 43 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 13 |
| Baclofen | Baclofen | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 13 |
| Clonidine Hcl | Clonidine Hcl | 36 | 15 |
| Estradiol | Estradiol | 36 | 13 |
| Lovastatin | Lovastatin | 35 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | 11 |
| Prednisone | Prednisone | 33 | 14 |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 23 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 14 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 18 |
| Synthroid | Levothyroxine Sodium | 28 | 11 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Diazepam | Diazepam | 26 | suppressed |
| Felodipine Er | Felodipine | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 17 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 11 |
| Risperidone | Risperidone | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Briviact | Brivaracetam | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Felbamate | Felbamate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,441.32 · 99 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, JARDIANCE, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error